Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies
Objective To assess the long-term safety profile of bimekizumab (BKZ) in patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA).Methods Safety data pooled from six integrated phase IIb/III studies in axSpA and PsA are reported (to the July 2022 data-cut for phase III) for patien...
Saved in:
| Main Authors: | Robert Landewé, Ana-Maria Orbai, Philip J Mease, Denis Poddubnyy, Lianne S Gensler, Vishvesh Shende, Richard B Warren, Luke Peterson, Alexander Marten, Ute Massow, Katy White, Barbara Ink, Rajan Bajracharya, Myriam Manente |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-04-01
|
| Series: | RMD Open |
| Online Access: | https://rmdopen.bmj.com/content/11/2/e005026.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies
by: Philip J. Mease, et al.
Published: (2024-08-01) -
Correction: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies
by: Philip J. Mease, et al.
Published: (2025-05-01) -
Summary of Research: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies
by: Philip J. Mease, et al.
Published: (2025-05-01) -
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL
by: Robert Landewé, et al.
Published: (2024-02-01) -
Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis
by: Laure Gossec, et al.
Published: (2024-02-01)